Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Published:2024-01 Issue:1 Volume:23 Page:37-45
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

McGarry Andrew,Rosanbalm Shane,Leinonen Mika,Olanow C Warren,To Dennis,Bell Adam,Lee Daniel,Chang Jamie,Dubow Jordan,Dhall Rohit,Burdick Daniel,Parashos Sotirios,Feuerstein Jeanne,Quinn Joseph,Pahwa Rajesh,Afshari Mitra,Ramirez-Zamora Aldolfo,Chou Kelvin,Tarakad Arjun,Luca Corneliu,Klos Kevin,Bordelon Yvette,St Hiliare Marie-Helene,Shprecher David,Lee Seulki,Dawson Ted M,Roschke Viktor,Kieburtz Karl

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference24 articles.

1. Diagnosis and treatment of Parkinson disease: a review;Armstrong;JAMA,2020

2. The oligomer hypothesis in α-synucleinopathy;Ono;Neurochem Res,2017

3. Alpha-synuclein: mechanisms of release and pathology progression in synucleinopathies;Brás;Cells,2021

4. Microglia response during Parkinson's disease: alpha-synuclein intervention;Ferreira;Front Cell Neurosci,2018

5. Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease;Garcia;Glia,2022

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How rival weight-loss drugs fare at treating obesity, diabetes and more;Nature;2024-09-03

2. Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases;Drug Discovery Today;2024-09

3. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27

4. What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?;Neurology;2024-08-27

5. Weight gain after Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease: is there a role for GLP-1 agonists?;Neurological Sciences;2024-08-10